Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Net Income (2016 - 2025)

United Therapeutics' Net Income history spans 17 years, with the latest figure at $364.3 million for Q4 2025.

  • For Q4 2025, Net Income rose 20.91% year-over-year to $364.3 million; the TTM value through Dec 2025 reached $1.3 billion, up 11.68%, while the annual FY2025 figure was $1.3 billion, 11.68% up from the prior year.
  • Net Income for Q4 2025 was $364.3 million at United Therapeutics, up from $338.7 million in the prior quarter.
  • Across five years, Net Income topped out at $364.3 million in Q4 2025 and bottomed at $28.3 million in Q1 2021.
  • The 5-year median for Net Income is $250.0 million (2023), against an average of $235.9 million.
  • The largest annual shift saw Net Income crashed 79.45% in 2021 before it skyrocketed 747.7% in 2022.
  • A 5-year view of Net Income shows it stood at $112.2 million in 2021, then increased by 17.74% to $132.1 million in 2022, then skyrocketed by 64.35% to $217.1 million in 2023, then skyrocketed by 38.78% to $301.3 million in 2024, then grew by 20.91% to $364.3 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Net Income are $364.3 million (Q4 2025), $338.7 million (Q3 2025), and $309.5 million (Q2 2025).